Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia.

Makropoulos DA, Achuthanandam R, Avery J, Wilson K, Brosnan K, Miller A, Nesspor T, Chroscinski D, Walker M, Egenolf D, Huang C, Bugelski PJ.

Curr Pharm Biotechnol. 2013;14(2):242-8.

2.

Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice.

Rafferty P, Egenolf D, Brosnan K, Makropoulos D, Jordan J, Meshaw K, Walker M, Volk A, Bugelski PJ.

J Immunotoxicol. 2012 Jan-Mar;9(1):43-55. doi: 10.3109/1547691X.2011.614646.

PMID:
22299716
3.

Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Martin PL, Bugelski PJ.

Br J Pharmacol. 2012 Jun;166(3):806-22. doi: 10.1111/j.1476-5381.2011.01812.x. Review.

4.

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Bugelski PJ, Martin PL.

Br J Pharmacol. 2012 Jun;166(3):823-46. doi: 10.1111/j.1476-5381.2011.01811.x. Review.

5.

A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes.

Scully MS, Ort TA, James IE, Bugelski PJ, Makropoulos DA, Deutsch HA, Pieterman EJ, van den Hoek AM, Havekes LM, Dubell WH, Wertheimer JD, Picha KM.

Exp Diabetes Res. 2011;2011:910159. doi: 10.1155/2011/910159. Epub 2011 Jun 30.

6.

Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.

Walker MR, Makropoulos DA, Achuthanandam R, Van Arsdell S, Bugelski PJ.

Int Immunopharmacol. 2011 Nov;11(11):1697-705. doi: 10.1016/j.intimp.2011.06.001. Epub 2011 Jun 29.

PMID:
21689786
7.

Development of a murine model of lymph node metastases suitable for immunotoxicity studies.

Egenolf DD, Rafferty P, Brosnan K, Walker M, Jordan J, Makropoulos D, Kavalkovich K, Watson S, Johns L, Volk A, Bugelski PJ.

J Pharmacol Toxicol Methods. 2011 May-Jun;63(3):236-49. doi: 10.1016/j.vascn.2010.12.001. Epub 2010 Dec 13.

PMID:
21156211
8.

Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.

Bugelski PJ, Volk A, Walker MR, Krayer JH, Martin P, Descotes J.

Int J Toxicol. 2010 Sep-Oct;29(5):435-66. doi: 10.1177/1091581810374654. Review.

PMID:
20884856
9.

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, Vafa O, Gunn G 3rd, Tam S, Sague S, Wang D, Brigham-Burke M, Dalmonte P, Emmell E, Pikounis B, Bugelski PJ, Zhou H, Scallon BJ, Giles-Komar J.

MAbs. 2010 Jul-Aug;2(4):428-39. Epub 2010 Jul 1.

10.

Monoclonal antibody-induced cytokine-release syndrome.

Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E.

Expert Rev Clin Immunol. 2009 Sep;5(5):499-521. doi: 10.1586/eci.09.31.

PMID:
20477639
11.

Effects of CNTO 530, an erythropoietin mimetic-IgG4 fusion protein, on embryofetal development in rats and rabbits.

Martin PL, Sachs C, Hoberman A, Jiao Q, Bugelski PJ.

Birth Defects Res B Dev Reprod Toxicol. 2010 Apr;89(2):87-96. doi: 10.1002/bdrb.20227.

PMID:
20077575
12.

Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.

Walker M, Makropoulos D, Achuthanandam R, Bugelski PJ.

Curr Opin Drug Discov Devel. 2010 Jan;13(1):124-35. Review.

PMID:
20047153
13.

Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice.

Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, Bugelski PJ, Murray LA, Marsters PA, Bunting RA, Flavell RA, Alexopoulou L, San Mateo LR, Griswold DE, Sarisky RT, Mbow ML, Das AM.

Respir Res. 2009 Jun 1;10:43. doi: 10.1186/1465-9921-10-43.

14.

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.

Sathyanarayana P, Houde E, Marshall D, Volk A, Makropoulos D, Emerson C, Pradeep A, Bugelski PJ, Wojchowski DM.

Blood. 2009 May 14;113(20):4955-62. doi: 10.1182/blood-2008-08-172320. Epub 2009 Mar 5.

15.

T-dependent antigen response (TDAR) tests: meta-analysis of results generated across multiple laboratories.

Bugelski PJ, Kim C.

J Immunotoxicol. 2007 Apr;4(2):159-64. doi: 10.1080/15476910701337126.

PMID:
18958725
16.

Sequential univariate gating approach to study the effects of erythropoietin in murine bone marrow.

Achuthanandam R, Quinn J, Capocasale RJ, Bugelski PJ, Hrebien L, Kam M.

Cytometry A. 2008 Aug;73(8):702-14. doi: 10.1002/cyto.a.20584.

17.

CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice.

Bugelski PJ, Capocasale RJ, Makropoulos D, Marshall D, Fisher PW, Lu J, Achuthanandam R, Spinka-Doms T, Kwok D, Graden D, Volk A, Nesspor T, James IE, Huang C.

J Biotechnol. 2008 Mar 20;134(1-2):171-80. doi: 10.1016/j.jbiotec.2007.12.005. Epub 2007 Dec 27.

PMID:
18242752
18.

Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice.

Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, Quinn J, Rafferty PA, O'Brien J, Emmell E, Bugelski PJ.

Cytometry A. 2008 Feb;73(2):148-59. doi: 10.1002/cyto.a.20512.

19.

Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice.

Snyder LA, Rudnick KA, Tawadros R, Volk A, Tam SH, Anderson GM, Bugelski PJ, Yang J.

J Thromb Haemost. 2008 Feb;6(2):306-14. Epub 2007 Nov 14.

20.

B cells and beyond: therapeutic opportunities targeting inflammation.

Liang B, Eaton-Bassiri A, Bugelski PJ.

Inflamm Allergy Drug Targets. 2007 Sep;6(3):142-9. Review.

PMID:
17897050
21.

Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model.

Berman DM, Cabrera O, Kenyon NM, Miller J, Tam SH, Khandekar VS, Picha KM, Soderman AR, Jordan RE, Bugelski PJ, Horninger D, Lark M, Davis JE, Alejandro R, Berggren PO, Zimmerman M, O'Neil JJ, Ricordi C, Kenyon NS.

Transplantation. 2007 Aug 15;84(3):308-15.

PMID:
17700154
22.

Pharmacodynamics of recombinant human erythropoietin in murine bone marrow.

Bugelski PJ, Nesspor T, Volk A, O'Brien J, Makropoulos D, Shamberger K, Fisher PW, James I, Graden D, Capocasale RJ.

Pharm Res. 2008 Feb;25(2):369-78. Epub 2007 Jul 4.

PMID:
17609863
23.

A statistical pattern recognition approach for determining cellular viability and lineage phenotype in cultured cells and murine bone marrow.

Quinn J, Fisher PW, Capocasale RJ, Achuthanandam R, Kam M, Bugelski PJ, Hrebien L.

Cytometry A. 2007 Aug;71(8):612-24.

24.

Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.

Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY.

Immunology. 2006 Nov;119(3):296-305.

25.

Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health.

Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, Coukos G, Damle N, Godfrey TE, Howell WM, Panelli MC, Perricone MA, Petricoin EF, Sauter G, Scheibenbogen C, Shivers SC, Taylor DL, Weinstein JN, Whiteside TL.

J Immunother. 2005 Mar-Apr;28(2):79-119.

PMID:
15725954
26.

Genetic aspects of immune-mediated adverse drug effects.

Bugelski PJ.

Nat Rev Drug Discov. 2005 Jan;4(1):59-69. Review.

PMID:
15688073
27.

Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.

Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, Rafferty P, Lakshminarayanan M, Griswold DE, Bugelski PJ, Das AM.

J Pharmacol Exp Ther. 2005 Apr;313(1):8-15. Epub 2005 Jan 11.

PMID:
15644434
28.
29.

Preclinical safety of recombinant human interleukin-18.

Herzyk DJ, Bugelski PJ, Hart TK, Wier PJ.

Toxicol Pathol. 2003 Sep-Oct;31(5):554-61.

PMID:
14692624
30.
31.

Immunopharmacology of recombinant human interleukin-18 in non-human primates.

Herzyk DJ, Soos JM, Maier CC, Gore ER, Narayanan PK, Nadwodny KL, Liu S, Jonak ZL, Bugelski PJ.

Cytokine. 2002 Oct 7;20(1):38-48.

PMID:
12441145
32.

Gene expression profiling for pharmaceutical toxicology screening.

Bugelski PJ.

Curr Opin Drug Discov Devel. 2002 Jan;5(1):79-89. Review.

PMID:
11865676
33.

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.

J Allergy Clin Immunol. 2001 Aug;108(2):250-7.

PMID:
11496242
34.

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

Toseland CD, Campbell S, Francis I, Bugelski PJ, Mehdi N.

Diabetes Obes Metab. 2001 Jun;3(3):163-70.

PMID:
11412280
35.

Maximization of signal derived from cDNA microarrays.

Wildsmith SE, Archer GE, Winkley AJ, Lane PW, Bugelski PJ.

Biotechniques. 2001 Jan;30(1):202-6, 208.

36.

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.

Clin Immunol. 2001 Feb;98(2):164-74.

PMID:
11161972
37.

Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice.

Herzyk DJ, Gore ER, Polsky R, Nadwodny KL, Maier CC, Liu S, Hart TK, Harmsen AG, Bugelski PJ.

Infect Immun. 2001 Feb;69(2):1032-43.

38.

A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology.

Bugelski PJ, Atif U, Molton S, Toeg I, Lord PG, Morgan DG.

Pharm Res. 2000 Oct;17(10):1265-72.

PMID:
11145233
39.

Nonlinear Dynamics in the Progression of Atherosclerotic Fatty Streaks: Morphometric Analysis.

Bugelski PJ, Maleeff BE, Klinkner AM, Louden CS, Hart TK.

Microsc Microanal. 2000 Nov;6(6):532-541.

PMID:
11116302
40.

Repeated acetaminophen dosing in rats: adaptation of hepatic antioxidant system.

O'Brien PJ, Slaughter MR, Swain A, Birmingham JM, Greenhill RW, Elcock F, Bugelski PJ.

Hum Exp Toxicol. 2000 May;19(5):277-83.

PMID:
10918522
41.

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK.

Hum Exp Toxicol. 2000 Apr;19(4):230-43.

PMID:
10918514
42.

Selective inhibition of phospholipases by atiprimod, a macrophage targeting antiarthritic compound.

Handler JA, Badger A, Genell CA, Klinkner AM, Kassis S, Waites CR, Bugelski PJ.

Toxicol Appl Pharmacol. 1999 Aug 15;159(1):9-17.

PMID:
10448120
43.

Evaluation of alamar blue reduction for the in vitro assay of hepatocyte toxicity.

Slaughter MR, Bugelski PJ, O'Brien PJ.

Toxicol In Vitro. 1999 Aug-Oct;13(4-5):567-9.

PMID:
20654517
44.

Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.

Badger AM, Handler JA, Genell CA, Herzyk D, Gore E, Polsky R, Webb L, Bugelski PJ.

Int J Immunopharmacol. 1999 Mar;21(3):161-76.

PMID:
10348366
45.
46.

Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs.

Herzyk DJ, Ruggieri EV, Cunningham L, Polsky R, Herold C, Klinkner AM, Badger A, Kerns WD, Bugelski PJ.

Toxicol Pathol. 1997 Jul-Aug;25(4):351-62.

PMID:
9280118
47.

A novel technique for mapping the lipid composition of atherosclerotic fatty streaks by en face fluorescence microscopy.

Klinkner AM, Bugelski PJ, Waites CR, Louden C, Hart TK, Kerns WD.

J Histochem Cytochem. 1997 May;45(5):743-53.

PMID:
9154162
48.

Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation.

Hart TK, Truneh A, Bugelski PJ.

AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1305-13.

PMID:
8891109
49.

Relationships between antibodies against human soluble complement receptor 1 (hsCR1) from various species.

Ruggieri EV, Bugelski PJ, Kaplan JM, Everitt D, Lipani J, Jorkasky DK, Boike SC, DeClement F, Moore FD Jr, Herzyk DJ.

J Clin Immunol. 1996 Mar;16(2):97-106.

PMID:
8690778
50.

Renal catabolism of recombinant human soluble CD4 after intravenous administration to male Sprague-Dawley rats.

Hepburn TW, Davis CB, Urbanski JJ, Smith BR, Schaefer WH, Carbonaro MA, Bugelski PJ.

Drug Metab Dispos. 1995 Oct;23(10):1044-50.

PMID:
8654191

Supplemental Content

Loading ...
Support Center